Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | AgenT-797 |
Trade Name | |
Synonyms | AgenT797|AgenT 797 |
Drug Descriptions |
AgenT-797 is an HLA-unmatched allogeneic invariant natural killer T-cell (iNKT) therapy, which potentially induces antitumor immune activity (Cancer Res (2023) 83 (8_Supplement): CT275, PMID: 38321023). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
AgenT-797 | AgenT-797 | 0 | 1 |
AgenT-797 + Balstilimab + Botensilimab + Paclitaxel + Ramucirumab | AgenT-797 Balstilimab Botensilimab Paclitaxel Ramucirumab | 0 | 1 |
AgenT-797 + Nivolumab | AgenT-797 Nivolumab | 0 | 1 |
AgenT-797 + Pembrolizumab | AgenT-797 Pembrolizumab | 0 | 1 |